Exagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $16.63 million versus the consensus estimate of $17.08 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.